Related Experiment Video
Updated: Oct 26, 2026

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice
Published on: July 16, 2014
[Gabapentinoids and COPD : analgesia or asphyxia ?]
Jeremy H Martin1, Thomas Agoritsas1, Anne Rossel1
1Service de médecine interne générale, Département de médecine, Hôpitaux universitaires de Genève, 1211 Genève 14.
Abstract:
Gabapentinoids are widely prescribed for patients with Chronic Obstructive Pulmonary Disease (COPD), despite safety warnings issued by several regulatory agencies regarding their potential respiratory depressant effects. Three large observational studies conducted in Canada, United Kingdom and Japan have been published between 2024 and 2025. They have consistently reported an association between the initiation of gabapentinoid therapy and a 20 to 40 % increase in the risk of COPD exacerbations. This review summarizes these findings, discusses their interpretation, their limits, and the implications for clinical practice.
Related Concept Videos
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Analgesia and Pain Management
Parenteral Anesthetics: Overview
Opioid Analgesics: Morphine and Other Natural Cogeners
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
CNS Depressants: Barbiturates and Benzodiazepines